Primary Hypertension Treatment Made Simple: What It Is and Key Medication Options Featuring SPH3127 Tablets
Primary hypertension remains one of the most widespread chronic conditions globally. 👉 Currently, approximately 1.2…
News
Mazdutide Injection Approved as China’s First Dual-Action Metabolic Agonist Targeting GLP-1 and GCG
The National Medical Products Administration (NMPA) has officially approved the marketing application for Mazdutide Injection…
Erlotinib Hydrochloride Tablets: A Foundational Milestone in the Era of EGFR-Targeted Therapy
In the fast-evolving landscape of lung cancer treatment, targeted therapies have reshaped the meaning of…
Anti-Tumor Therapies: Key Drugs and Modern Cancer Treatment Approaches
Cancer remains one of the most significant global health challenges, affecting millions of people every…
Why Omega-3-Acid Ethyl Esters Matter: A Clinically Tested Solution for Severe Hypertriglyceridemia
🍔 In recent years, the prevalence of metabolic disorders has continued to rise, driven by…
NBP (Butylphthalide)—A Breakthrough in Neuroprotection for Ischemic
Acute ischemic stroke remains a major global health challenge, leading to high morbidity, mortality, and…
Luvometinib Tablets Approved in China 丨A Next-Generation MEK1/2 Inhibitor for Rare MAPK-Driven Tumors
China’s National Medical Products Administration (NMPA) has officially approved Luvometinib Tablets (brand name Fumaining®, development code…
Innovative Drug Delivery Systems: Transforming Modern Medicine
When it comes to medicine, most people assume that taking a drug is enough for…
Fosrolapitant and Palonosetron Hydrochloride Injection Receives Approval丨Offering New Hope for Chemotherapy-Induced Nausea and Vomiting Management
Recently, Fujian Shengdian Pharmaceutical Co., Ltd., a subsidiary of Hengrui Medicine, received approval from the…
What is Innovative Drug? Exploring the Future of Medicine
In the rapidly evolving field of healthcare, the term “innovative drug” has gained significant attention.…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights